Research and laboratory use only. Not for human consumption.
Retatrutide
Retatrutide is an investigational synthetic peptide developed by Eli Lilly and engineered to activate three metabolically important receptors: glucose-dependent insulinotropic polypeptide receptor, glucagon-like peptide-1 receptor and the glucagon receptor. Clinical development has progressed through Phase 1, Phase 2 and multiple Phase 3 trials investigating obesity, type 2 diabetes and obesity- related complications.
What is Retatrutide?
Retatrutide is an investigational multi-receptor peptide agonist developed by Eli Lilly and Company.
It is designed as a single molecule capable of activating three related G-protein-coupled receptors: GIPR, GLP-1R and GCGR.
This combination distinguishes Retatrutide from GLP-1 receptor agonists such as semaglutide and from dual GIP/GLP-1 receptor agonists such as tirzepatide.
The underlying hypothesis is that combining several nutrient-responsive endocrine pathways within a single peptide may produce complementary effects on appetite, glucose metabolism, substrate utilization and energy expenditure.
Retatrutide is therefore frequently described as a triple hormone-receptor agonist .
Early studies progressed rapidly after preclinical research demonstrated potent metabolic effects, and human development subsequently advanced through Phase 1, Phase 2 and a large Phase 3 programme.
What does Retatrutide mean?
During early research, Retatrutide was primarily identified by the development code LY3437943.
The generic name Retatrutide was assigned as the compound progressed further through clinical development.
Unlike abbreviations such as GHRP-6, Retatrutide is not an acronym describing its amino-acid sequence or mechanism.
Structurally, Retatrutide is a synthetic modified and lipidated peptide rather than the unmodified sequence of a naturally occurring human hormone.
The molecule was engineered specifically to combine activity at three receptors within a pharmacokinetic profile suitable for prolonged systemic exposure.
One peptide — three metabolic receptors
Retatrutide emerged from research seeking to combine GLP-1, GIP and glucagon receptor pharmacology within a single long-acting molecule.
From incretin biology to triple agonism
GLP-1 receptor agonism had already become an established strategy for treatment of type 2 diabetes and obesity.
Development of dual-receptor molecules subsequently demonstrated that more than one nutrient-regulated signalling pathway could be combined within a single peptide.
Researchers at Eli Lilly investigated whether adding glucagon-receptor activity to combined GIP and GLP-1 signalling might further alter energy balance.
The resulting molecule, LY3437943, showed activity at all three receptors.
Experimental work published in Cell Metabolism in 2022 reported that Retatrutide had balanced glucagon and GLP-1 receptor activity with comparatively stronger GIP receptor activity in vitro.
Positive human Phase 1 findings led to larger Phase 2 trials and ultimately the global TRIUMPH and TRANSCEND Phase 3 programmes.
A modified 39-residue peptide
Retatrutide is based on a 39-residue peptide backbone and contains non-standard residues, terminal modification and a lipid-linked side chain. A simple natural amino-acid sequence alone therefore does not completely describe the active molecule.
Why target three receptors?
Retatrutide was designed around the idea that several endocrine pathways involved in nutrient sensing can provide complementary metabolic effects.
GLP-1 receptor signalling is strongly associated with reduced food intake and improved glucose-dependent insulin secretion.
GIP receptor signalling also influences insulin secretion and interacts with broader metabolic pathways.
The addition of glucagon receptor agonism is particularly interesting because glucagon signalling can increase hepatic substrate turnover and energy expenditure.
In the original preclinical programme, researchers reported that GCGR-mediated increases in energy expenditure added to reductions in calorie intake driven by GIPR and GLP-1R activity.
How does Retatrutide affect energy balance?
The clinical effect is likely generated by coordinated signalling across appetite, pancreatic, hepatic and energy-expenditure pathways rather than through one isolated mechanism.
Appetite Regulation
Incretin-related central nervous system signalling can reduce appetite and energy intake.
Glucose Regulation
GIP and GLP-1 receptor activity can influence glucose-dependent insulin secretion and glycaemic control.
Energy Expenditure
Preclinical research indicates that glucagon-receptor activity can contribute additional energy expenditure.
Substrate Utilisation
Triple receptor signalling can influence lipid, carbohydrate and hepatic metabolic pathways.
What is Retatrutide being investigated for?
Clinical development has expanded beyond body- weight reduction to investigate several major complications associated with obesity and metabolic disease.
Obesity
The largest clinical programme is evaluating substantial and sustained body-weight reduction in adults with obesity or overweight.
Type 2 Diabetes
TRANSCEND trials are investigating glycaemic control and body weight in people with type 2 diabetes.
Cardiometabolic Disease
Trials include people with severe obesity and established cardiovascular disease.
Obesity Complications
Research includes obstructive sleep apnoea and knee osteoarthritis associated with obesity.
The landmark Phase II obesity trial
The 2023 Phase II study generated substantial scientific interest after demonstrating large dose-dependent reductions in body weight over 48 weeks.
NCT04881760
Multicentre, double-blind, placebo-controlled investigation in adults with obesity or overweight plus a weight-related condition.
The Phase II study enrolled 338 adults and compared several Retatrutide treatment groups with placebo.
Participants had obesity, or overweight with at least one weight-related condition, and did not have diabetes.
The trial demonstrated a clear dose-response relationship for reduction in body weight.
By week 48, mean weight reduction in the highest treatment group reached 24.2% from baseline, compared with 2.1% with placebo.
Importantly, average weight-loss curves had not clearly plateaued by the end of the 48-week treatment period.
This result was one of the reasons Retatrutide rapidly progressed into a large Phase III development programme.
Body-weight change at 48 weeks
Mean changes reported in the peer-reviewed Phase II obesity trial. These results describe a controlled clinical study and are not predictions of individual response.
Least-squares mean percentage change in body weight at 48 weeks.
Mean weight reduction across the combined 4 mg treatment groups.
Mean weight reduction across the combined 8 mg treatment groups.
Compared with −2.1% in the placebo group at week 48.
Treatment groups are shown because they are necessary to accurately report the published clinical evidence. They should not be interpreted as instructions, dosing guidance or recommendations for use of non-approved research material.
The TRIUMPH programme
By 2026, several pivotal Phase III Retatrutide studies had produced positive topline results. Some detailed results have been presented at scientific meetings, while additional complete peer-reviewed publications remain forthcoming.
Obesity without diabetes
−28.3%Lilly reported an average 28.3% body- weight reduction at 80 weeks in participants receiving the highest studied treatment level.
45.3% of participants in that group achieved at least 30% body-weight reduction.
Obesity + Type 2 Diabetes
−20.8%Lilly reported average weight loss of up to 20.8% over 80 weeks in adults with obesity or overweight and type 2 diabetes.
The programme simultaneously assessed glycaemic endpoints including A1C.
Severe obesity + cardiovascular disease
−22.6%Lilly reported average weight reduction of up to 22.6% at 80 weeks among adults with severe obesity and established cardiovascular disease.
Participants could have cardiovascular disease with or without type 2 diabetes.
TRIUMPH-2 and TRIUMPH-3 figures announced in July 2026 are sponsor-reported topline findings. Detailed datasets are expected to undergo presentation and publication. They should therefore be distinguished from already peer-reviewed Phase II evidence.
Research into obesity-related complications
The Retatrutide development programme has been structured to examine whether large reductions in body weight are accompanied by improvements in metabolic and mechanical complications of obesity.
Type 2 Diabetes
Phase III studies have reported reductions in A1C together with substantial body- weight loss.
Obstructive Sleep Apnoea
TRIUMPH-1 substudies investigated changes in sleep-apnoea severity alongside weight reduction.
Knee Osteoarthritis
Clinical research has assessed changes in knee pain among participants with obesity and osteoarthritis.
Cardiovascular Disease
TRIUMPH-3 specifically enrolled adults with severe obesity and established cardiovascular disease.
What has been observed in clinical trials?
Retatrutide has now been studied in substantial numbers of human participants, but its complete long-term safety profile is still being defined because clinical development remains ongoing.
Gastrointestinal Effects
Nausea, diarrhoea, vomiting and related gastrointestinal events have been among the most commonly reported adverse events in clinical studies.
Dose Relationship
Gastrointestinal adverse events in Phase II were dose-related and generally more common at higher exposure levels.
Heart Rate
Phase II research identified dose-dependent increases in heart rate that peaked during treatment and later declined.
Long-Term Data
Large Phase III programmes are continuing to expand understanding of longer-term safety across different metabolic populations.
Clinical-trial safety findings relate to carefully manufactured investigational pharmaceutical material used within controlled research protocols. They should not be treated as evidence that independently manufactured products claiming to contain Retatrutide have the same identity, purity or safety profile.
How strong is the evidence?
Retatrutide now has evidence extending from molecular pharmacology through large Phase III clinical trials. Regulatory review has not yet been completed.
Molecular Pharmacology
Activity at GIP, GLP-1 and glucagon receptors is well characterized.
Phase I Evidence
Human pharmacokinetics, tolerability and proof-of-concept metabolic effects have been established.
Phase II Evidence
Peer-reviewed randomized trials provide substantial evidence for body-weight reduction.
Phase III Evidence
Multiple pivotal trials have reported positive results, with additional publications and regulatory review still pending.
Where is Retatrutide now?
As of August 2026, Retatrutide remains an investigational medicine. Several pivotal Phase III studies have reported positive results, but regulatory marketing approval has not yet been granted.
Late-stage investigational metabolic peptide
Retatrutide is considerably further advanced than most compounds commonly described as research peptides, but it remains an investigational medicine until regulatory approval is granted.
What remains uncertain?
Factors affecting Retatrutide stability
Retatrutide is a large modified and lipidated peptide. Stability should be defined from analytical data for the exact material, formulation and chemical form being investigated rather than inferred from generic peptide handling rules.
Temperature
Temperature can influence peptide degradation, aggregation and long-term chemical integrity.
Moisture
Humidity can influence physical and chemical stability of lyophilized peptide material.
Solution Conditions
Buffer, pH, concentration and solvent environment can substantially alter the stability of modified peptides.
Material Specification
Molecular identity, lipidation state, purity, counter-ion and aggregation state should be defined analytically.
Late-stage investigational triple hormone-receptor agonist
Retatrutide is a 39-residue modified peptide with activity at GIP, GLP-1 and glucagon receptors. It has progressed through Phase I and Phase II research and is currently supported by multiple pivotal Phase III programmes.
Positive Phase III findings have now been reported from TRIUMPH-1, TRIUMPH-2 and TRIUMPH-3, including substantial reductions in body weight in several populations.
Eli Lilly has announced that it plans to submit a regulatory application to the U.S. FDA in the first quarter of 2027.
Retatrutide is not currently approved by the FDA or any other regulatory agency and should not be described as an approved obesity or diabetes medicine.
ASA Research Labs provides this information for scientific and educational purposes only. Nothing on this page provides prescribing, administration or dosing guidance, or constitutes a recommendation for human use of research material.
Selected scientific references
Selected peer-reviewed publications, registered clinical trials and recent Phase III development reports covering the discovery, pharmacology and clinical development of Retatrutide.
Scientific research information only
This profile is provided for scientific and educational information. Retatrutide is an investigational pharmaceutical peptide undergoing late-stage clinical development and is not currently an approved medicine. Discussion of Phase I, Phase II or Phase III clinical trials, body-weight changes, glucose regulation, sleep apnoea, osteoarthritis, cardiovascular disease or other outcomes describes published or reported scientific research and does not constitute prescribing advice. Results obtained with pharmaceutical-grade investigational Retatrutide in controlled clinical trials should not be extrapolated to unrelated research products. This page does not provide instructions for administration, dosing or human use.